Russell Investments Group Ltd. Has $1.19 Million Holdings in Catalent, Inc. (NYSE:CTLT)

Russell Investments Group Ltd. lessened its position in shares of Catalent, Inc. (NYSE:CTLT – Get Rating) by 16.3% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 26,240 shares of the company’s stock after selling 5,117 shares during the quarter. Russell Investments Group Ltd.’s holdings in Catalent were worth $1,186,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Veritas Asset Management LLP boosted its holdings in shares of Catalent by 60.5% during the 4th quarter. Veritas Asset Management LLP now owns 11,169,815 shares of the company’s stock worth $502,753,000 after buying an additional 4,212,040 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Catalent by 5.2% in the 3rd quarter. BlackRock Inc. now owns 16,086,469 shares of the company’s stock worth $1,164,016,000 after purchasing an additional 792,923 shares in the last quarter. Artisan Partners Limited Partnership lifted its holdings in shares of Catalent by 12.2% in the 3rd quarter. Artisan Partners Limited Partnership now owns 5,868,803 shares of the company’s stock worth $424,667,000 after purchasing an additional 636,031 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Catalent by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 18,971,342 shares of the company’s stock worth $2,103,921,000 after purchasing an additional 492,071 shares in the last quarter. Finally, New York State Common Retirement Fund lifted its holdings in shares of Catalent by 62.2% in the 4th quarter. New York State Common Retirement Fund now owns 839,076 shares of the company’s stock worth $37,767,000 after purchasing an additional 321,639 shares in the last quarter. Institutional investors and hedge funds own 99.38% of the company’s stock.

Catalent Stock Down 1.8 %

Shares of NYSE:CTLT opened at $37.44 on Thursday. Catalent, Inc. has a 12-month low of $31.45 and a 12-month high of $115.33. The stock has a fifty day simple moving average of $51.22 and a two-hundred day simple moving average of $52.92. The company has a current ratio of 1.91, a quick ratio of 1.38 and a debt-to-equity ratio of 0.86. The stock has a market capitalization of $6.74 billion, a price-to-earnings ratio of 16.57, a PEG ratio of 4.64 and a beta of 1.17.

Insider Transactions at Catalent

In other news, SVP Mario Gargiulo sold 678 shares of the business’s stock in a transaction on Monday, May 1st. The stock was sold at an average price of $49.86, for a total value of $33,805.08. Following the completion of the transaction, the senior vice president now owns 5,676 shares in the company, valued at $283,005.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, SVP Mario Gargiulo sold 678 shares of Catalent stock in a transaction on Monday, May 1st. The stock was sold at an average price of $49.86, for a total value of $33,805.08. Following the completion of the sale, the senior vice president now owns 5,676 shares of the company’s stock, valued at $283,005.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Manja Boerman sold 1,446 shares of Catalent stock in a transaction on Monday, May 1st. The stock was sold at an average price of $49.86, for a total value of $72,097.56. Following the completion of the sale, the insider now directly owns 14,414 shares of the company’s stock, valued at approximately $718,682.04. The disclosure for this sale can be found here. Company insiders own 0.58% of the company’s stock.

Wall Street Analysts Forecast Growth

CTLT has been the subject of several analyst reports. Deutsche Bank Aktiengesellschaft increased their target price on shares of Catalent from $29.00 to $37.00 in a report on Monday. William Blair lowered Catalent from an “outperform” rating to a “market perform” rating in a report on Friday, April 14th. Robert W. Baird dropped their price target on Catalent from $53.00 to $35.00 in a report on Monday. Bank of America cut Catalent from a “neutral” rating to an “underperform” rating and set a $28.00 price objective on the stock. in a research report on Monday, May 8th. Finally, StockNews.com began coverage on Catalent in a research report on Thursday, May 18th. They issued a “sell” rating on the stock. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Catalent has an average rating of “Hold” and a consensus target price of $67.55.

Catalent Profile

(Get Rating)

Catalent, Inc is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.